Log in to your Inderes Free account to see all free content on this page.
Magle Chemoswed Holding
4.22 SEK
+2.93 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.93 %
-7.46 %
-53.11 %
-76.02 %
-77.19 %
-83.89 %
-87.96 %
-88.23 %
-79.00 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
127.71M SEK
Turnover
150.1 SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.5.
2026
General meeting '26
26.5.
2026
Extraordinary general meeting '26
31.5.
2026
Interim report Q1'26
All
Press releases
3rd party
ShowingAll content types
Notice to extraordinary general meeting in Magle Chemoswed Holding AB (publ)
Magle Group announces resignation of board member
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio